Join us at #EAU23 for our Rapid Fire Debate #BladderCancer Session Sat, March 11, 3:15 pm Marek Babjuk Joan Palou Redorta Paolo Gontero splernerMD Roger Li Morgan Roupret Laura S. Mertens Prof Param Mariappan 🇬🇧 🇲🇾 Jørgen Bjerggaard jim catto Alex Masson-Lecomte Shahrokh F. Shariat Andrea Necchi Arnulf Stenzl European Association of Urology (EAU)

Tillykke til overlæge og professor Jørgen Bjerggard Jensen på Urinvejskirurgi, som i år løber med JCD-prisen for at være en særligt engageret og dygtig ph.d.-vejleder på HealthAU health.au.dk/display/artike… #forskning #phd #dkvid #dkforsk

Karin Birkenkamp-Demtröder Frederik Prip Sia Viborg Lindskrog Emil Christensen Philippe Lamy Jørgen Bjerggaard

The Rapid Fire Debate #Team #EAU23 #BladderCancer Marek Babjuk Joan Palou Redorta Paolo Gontero splernerMD Roger Li Morgan Roupret Laura S. Mertens Prof Param Mariappan Jørgen Bjerggaard jim catto Alex Masson-Lecomte Shahrokh F. Shariat Andrea Necchi Arnulf Stenzl European Association of Urology (EAU)

Basic TURBT course for junior residents in Urology with lots of Hands-on simulation training, know your instruments, live surgery and excellents lectures. A special Thanks to Jørgen Bjerggaard Maria Skydt Lindgren #olympusdenmark #MidtSim #auh for the collaboration and making it a great day

Workshop with the official best PI in Denmark, what a treat :) Jørgen Bjerggaard @Ilisimatusarfik #research #PhD #phdstudent

Antibiotics may be reduced during follow-up for NMIBC. Thomas Dreyer from Denmark presenting at #AUA2023 in Chicago Jørgen Bjerggaard Nessn Azawi NUF2023 European Association of Urology (EAU)

💬Happy to share the Special Issue "Time for a Paradigm Shift in Non-Muscle-Invasive Bladder Cancer (Volume II)" edited by Prof. Dr. Jørgen Bjerggaard J. Jørgen Bjerggaard Aarhus University❗️👏 ⏰Deadline for manuscript submissions: 20 March 2024. 🔗Find out more: mdpi.com/journal/cancer…

Min uundværlige sekretær udbygger familien lidt, så der er mulighed for at prøve kræfter med at arbejde i verdens bedste forskningsenhed - med en utrolig flink chef.. Hvis nogen vil høre mere eller søge jobbet, så send dem endelig denne vej:-) midtjob.dk/ad/professorse…

Preliminary data from our RCT in urinary diversion following radical #cystectomy in #bladdercancer sciencedirect.com/science/articl…

New special edition coming up: Treatment of Bladder Cancer: From Past to Future mdpi.com/si/191676 #mdpijcm via JCM MDPI

Kom maj, du søde milde… Følg med på turen på FB og Instagram blacrest.com/opvarmfod/

Join us April 5th for the 7th edition of Rapid Fire Debates in #BladderCancer #EAU2024 #EAU24 Morgan Roupret Sarah P. Psutka MD MS Andrea Necchi Joan Palou Redorta evacomperat Philippe spiess Benjamin Pradere Jørgen Bjerggaard 💙alison birtle Marek Babjuk Paolo Gontero jim catto Peter Black Arnulf Stenzl European Association of Urology (EAU)

Many thanks for the kind invitation Aarhus University to examine for the PhD. Great hospitality Jorgen, Lars Dyrskjøt and team - was a pleasure! See you at #EAU24.

Pleasure to have you here in Aarhus Prof Param Mariappan 🇬🇧 🇲🇾 🦈👍

Thank you to all the Faculty for a very successful 7th edition of Rapid Fire Debates in #BladderCancer #EAU2024 #EAU24 Morgan Roupret Sarah P. Psutka MD MS Andrea Necchi Joan Palou Redorta evacomperat Philippe spiess Benjamin Pradere Jørgen Bjerggaard 💙alison birtle Marek Babjuk Paolo Gontero jim catto

60 years ago first #renal_transplant performed in Aarhus #AUHdk #urology

urothelial cancer highlight #ESMO24 New ADC data (1st line DV/pembo, EGFR/HER3),TAR200 (pretzel) in MIBC (SUNRISE4), EV/pembro biomarkers (EV302), adjuvant (TOMBOLA) and neoadjuvant (VOLGA) ctDNA, updates on adjuvant pembro (AMBASSADOR), neoadjuvant chemo +/- durvalumab (NIAGRA)

Exited to share the first results from the TOMBOLA trial presented at #ESMO24 by Jørgen Bjerggaard. We used tumor informed (WES; ddPCR) ctDNA analysis to guide Atezolizumab treatment after cystectomy using longitudinally collected blood samples. Key findings: •CtDNA-negative

#ESMO24 - Tombola trial - Serial measurements of cDNA following NAC and RC is a highly specific method to identify patients that might benefit from early immunotherapy at a time of minimal metastatic disease